Thomas Reiser: Final Day as Executive Director – Closing a Remarkable Chapter at ISTH
Thomas Reiser, Executive Director at the International Society on Thrombosis and Haemostasis, shared a post on LinkedIn:
“Today is my final day as Executive Director at the International Society on Thrombosis and Haemostasis (ISTH).
I close this remarkable 14+ year chapter with immense gratitude for the trust placed in me, for the privilege of serving a mission and organization I believe so deeply in, and for the many extraordinary people who made this journey meaningful every step of the way.
To the ISTH team, Council, volunteers, members, partners, and the hashtag#thrombosis and hashtag#hemostasis community around the world: Thank you for allowing me to be part of this amazing community, the collaboration, dedication, and the friendships that will stay with me long after today.
I leave with great pride for all we have been able to accomplish together.
At the same time, I look forward to continuing to create impact, wherever the next chapter may lead me.
With heartfelt thanks and deep appreciation.”

Find more posts featuring Thomas Reiser on Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies